BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30373552)

  • 1. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
    Seeliger H; Pozios I; Assmann G; Zhao Y; Müller MH; Knösel T; Kreis ME; Bruns CJ
    BMC Cancer; 2018 Oct; 18(1):1049. PubMed ID: 30373552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
    Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma.
    Maréchal R; Demetter P; Nagy N; Berton A; Decaestecker C; Polus M; Closset J; Devière J; Salmon I; Van Laethem JL
    Br J Cancer; 2009 May; 100(9):1444-51. PubMed ID: 19352387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma.
    Nguyen Kovochich A; Arensman M; Lay AR; Rao NP; Donahue T; Li X; French SW; Dawson DW
    Cancer; 2013 Feb; 119(3):529-39. PubMed ID: 22914903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
    Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
    Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
    Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
    Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
    Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma.
    Fu XL; Liu DJ; Yan TT; Yang JY; Yang MW; Li J; Huo YM; Liu W; Zhang JF; Hong J; Hua R; Chen HY; Sun YW
    Sci Rep; 2016 Sep; 6():33535. PubMed ID: 27628540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of voltage-gated sodium channel Nav1.5 in non-metastatic colon cancer and its associations with estrogen receptor (ER)-β expression and clinical outcomes.
    Peng J; Ou Q; Wu X; Zhang R; Zhao Q; Jiang W; Lu Z; Wan D; Pan Z; Fang Y
    Chin J Cancer; 2017 Nov; 36(1):89. PubMed ID: 29122010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.